financetom
GVA
financetom
/
Industrials
/
GVA
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Granite Construction IncorporatedGVA
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

Granite Construction Incorporated operates as an infrastructure contractor and a construction materials producer in the United States.

The company operates through two segments, Construction and Materials segments. The Construction segment engages in the construction and rehabilitation of roads, pavement preservation, bridges, rail lines, airports, marine ports, dams, reservoirs, aqueducts, infrastructure, and site development for use by the public.

The Materials segment is involved in the production of aggregates and asphalt for internal use, as well as for sale to third parties.

It also focuses on water-related construction for municipal agencies, commercial water suppliers, industrial facilities, and energy companies; and constructs various complex projects, including infrastructure/site development, mining, public safety, tunnel, solar, and power projects.

In addition, the company offers site preparation, mining, and infrastructure services for residential development, energy development, commercial and industrial sites, and other facilities; and provides construction management professional services.

It serves federal agencies, state departments of transportation, local transit authorities, county and city public works departments, school districts and developers, utilities, contractors, landscapers, manufacturers of products requiring aggregate materials, retailers, homeowners, farmers, brokers, and private owners of industrial, commercial, and residential sites.

The company was incorporated in 1922 and is headquartered in Watsonville, California.

Latest News >
Apple Shipments Fail to Match Global Smartphone Sales Growth
Apple Shipments Fail to Match Global Smartphone Sales Growth
Nov 27, 2024
06:55 AM EST, 11/27/2024 (MT Newswires) -- Apple ( AAPL ) failed to benefit from a forecast 6.2% global rise in smartphone shipments in 2024, an International Data Corporation quarterly report said Tuesday. Apple's ( AAPL ) iOS is expected to grow a modest 0.4% in 2024, stymied by challenges in China, the US, and Europe, the report said. Meanwhile,...
Frontline Posts Mixed Q3 Amid Seasonal Tanker Headwinds And Geopolitical Challenges: Details
Frontline Posts Mixed Q3 Amid Seasonal Tanker Headwinds And Geopolitical Challenges: Details
Nov 27, 2024
Frontline Plc ( FRO ) shares are down following mixed third-quarter results. Revenue rose 29.9% year-over-year to $490.4 million, surpassing the $361.42 million consensus. Reported spot TCEs for VLCCs, Suezmax tankers, and LR2/Aframax tankers were $39,600 (vs. $42,500 last year), $39,900 (vs. $37,600 last year) and $36,000 (vs. $33,900 prior year) per day. In the quarter, ballast days totaled 947...
Quarterhill Wins Two Contracts in Idaho Worth US$3.4 Million for Weigh Station Upgrades, Maintenance
Quarterhill Wins Two Contracts in Idaho Worth US$3.4 Million for Weigh Station Upgrades, Maintenance
Nov 27, 2024
06:54 AM EST, 11/27/2024 (MT Newswires) -- Quarterhill ( QTRHF ) on Wednesday said it has been awarded two contracts valued at US$3.4 million for system upgrades and maintenance at commercial vehicle enforcement stations operated by the Idaho State Police. Quarterhill ( QTRHF ) has been contracted by the Idaho Transportation Department to install new components and upgrade the Inkom...
BeiGene's Tevimbra Gets Approval From European Commission as Treatment for Cancer Patients
BeiGene's Tevimbra Gets Approval From European Commission as Treatment for Cancer Patients
Nov 27, 2024
06:56 AM EST, 11/27/2024 (MT Newswires) -- BeiGene Ltd ( BGNE ) said Wednesday that the European Commission has approved Tevimbra in combination with chemotherapy for the first-line treatment of esophageal squamous cell carcinoma and gastric or gastroesophageal junction adenocarcinoma. The approval is based on results from BeiGene's ( BGNE ) RATIONALE-306 and RATIONALE-305 phase 3 trials, which evaluated the...
Copyright 2023-2025 - www.financetom.com All Rights Reserved